Abstract
Dysregulated expression of microRNAs (miRNAs) in various tissues has been associated with a variety of diseases, including cancers. Here we demonstrate that miRNAs are present in the serum and plasma of humans and other animals such as mice, rats, bovine fetuses, calves, and horses. The levels of miRNAs in serum are stable, reproducible, and consistent among individuals of the same species. Employing Solexa, we sequenced all serum miRNAs of healthy Chinese subjects and found over 100 and 91 serum miRNAs in male and female subjects, respectively. We also identified specific expression patterns of serum miRNAs for lung cancer, colorectal cancer, and diabetes, providing evidence that serum miRNAs contain fingerprints for various diseases. Two non-small cell lung cancer-specific serum miRNAs obtained by Solexa were further validated in an independent trial of 75 healthy donors and 152 cancer patients, using quantitative reverse transcription polymerase chain reaction assays. Through these analyses, we conclude that serum miRNAs can serve as potential biomarkers for the detection of various cancers and other diseases.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Duffy MJ . Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38:225–262.
Thomas CM, Sweep CG . Serum tumor markers: past, state of the art, and future. Int J Biol Markers 2001; 16:73–86.
Duffy MJ . Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007; 18:175–184.
Roulston JE . Limitations of tumour markers in screening. Br J Surg 1990; 77:961–962.
Esquela-Kerscher A, Slack FJ . Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259–269.
Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857–866.
Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
Tang F, Hajkova P, Barton SC, Lao K, Surani MA . MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34:e9.
Hafner M, Landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008; 44:3–12.
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257–2261.
Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007; 67:5600–5605.
Ward DG, Suggett N, Cheng Y, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94:1898–1905.
He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102:19075–19080.
Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27:3845–3855.
Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25:387–392.
El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2004; 50:564–573.
Tsang JC, Lo YM . Circulating nucleic acids in plasma/serum. Pathology 2007; 39:197–207.
Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008; 54:482–490.
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141:672–675.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105:10513–10518.
Acknowledgements
We thank Drs Fengyong Liu and Sheng Luan at UC Berkeley, USA, for their discussion and help with the writing of the manuscript. This work was supported by grants from the National Natural Science Foundation of China (no. 30225037, 30471991, 30570731), National Basic Research Program of China (973 Program) (no. 2006CB503909, 2004CB518603), the “111” Project, and the Natural Science Foundation of Jiangsu Province (no. BK2004082, BK2006714).
Author information
Authors and Affiliations
Corresponding authors
Supplementary information
Supplementary Table 1
Serum miRNAs detected by Solexa in healthy male and female subjects (PDF 11 kb)
Supplementary Table 2
miRNAs detected by Solexa in the serum and cell of healthy subjects (PDF 13 kb)
Supplementary Table 3
miRNAs detected by Solexa in normal serum (NS) and lung cancer serum (LCS) subjects (PDF 14 kb)
Supplementary Table 4
miRNAs detected by Solexa in lung cancer serum (LCS) and lung cancer cell (LCC) subjects (PDF 14 kb)
Supplementary Table 5
microRNA primer information. (PDF 14 kb)
Rights and permissions
About this article
Cite this article
Chen, X., Ba, Y., Ma, L. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 997–1006 (2008). https://doi.org/10.1038/cr.2008.282
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/cr.2008.282
Keywords
This article is cited by
-
MicroRNAs and Cardiovascular Disease Risk
Current Cardiology Reports (2024)
-
Evaluation of capillary miR-122 as a prognostic biomarker of paracetamol-induced liver toxicity
Molecular Biology Reports (2024)
-
Evaluation of P-glycoprotein-targeting circulating microRNAs as peripheral biomarkers for medically intractable epilepsy
Acta Epileptologica (2023)
-
Human cytomegalovirus-encoded microRNAs expression profile in plasma of patients with aortic dissection
Journal of Cardiothoracic Surgery (2023)
-
Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles
Nature Communications (2023)